Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Digital PCR Market - A Global and Regional Analysis: Focus on Type, Application, End User, and Country Analysis - Analysis and Forecast, 2024-2034" report has been added to ResearchAndMarkets.com's offering.
The global digital PCR market, initially valued at $678.1 million in 2023, is poised for substantial growth, projected to surge to $3.35 billion by 2034, marking a remarkable compound annual growth rate (CAGR) of 15.75% over the period from 2024 to 2034.
The market has been experiencing significant double-digit growth, primarily fueled by the rising adoption of personalized medicine to screen and diagnose genetic disorders. This approach tailors medical treatment to the unique characteristics of each patient, with digital PCR (dPCR) playing a crucial role by enabling the detection and quantification of rare genetic mutations linked to various cancers.
Additionally, the growing prevalence of infectious diseases is driving the demand for dPCR as healthcare providers seek rapid and accurate diagnostic solutions. Technological advancements have also contributed to market expansion, with innovations such as droplet digital PCR, nanoplate technology, and microfluidic platforms enhancing the capabilities of digital PCR.
The digital PCR (dPCR) market is currently experiencing significant growth, fueled by cutting-edge technology and strategic collaborations that improve diagnostic capabilities. For instance, the partnership between Bio-Rad Laboratories and Oncocyte Corporation is crucial for developing solutions for transplant monitoring, highlighting dPCR's role in personalized medicine.
Additionally, major companies such as Thermo Fisher Scientific have been accelerating the use of dPCR in oncology and infectious disease diagnostics, i.e., their recent launch of the AutoRun dPCR Suite, which is designed to enhance laboratory efficiency. The increasing acknowledgment of dPCR's ability to detect low-abundance mutations is further driving its importance for tailored treatment approaches. With ongoing innovations and supportive regulations, the dPCR market is poised for substantial expansion, ultimately leading to better patient outcomes through advanced molecular diagnostics.
Industrial Impact
The digital PCR (dPCR) market has significantly shaped the landscape of molecular diagnostics, driven by key players such as Bio-Rad Laboratories, Thermo Fisher Scientific, and QIAGEN. These companies leverage innovative technologies to provide highly sensitive and precise solutions for applications in oncology, infectious diseases, and genetic testing. dPCR systems, known for their exceptional accuracy in quantifying nucleic acids, facilitate the detection of low-abundance mutations, which is crucial for personalized treatment strategies.
The industrial impact of dPCR extends beyond diagnostics, i.e., it plays a vital role in drug development and clinical trials by providing reliable data on patient responses and treatment efficacy. This is particularly evident in oncology, where dPCR helps identify specific biomarkers that guide targeted therapies. Additionally, the integration of dPCR into public health initiatives enhances disease monitoring and outbreak response capabilities.
As dPCR technologies continue to evolve and regulatory support increases, the market's influence on research and clinical practices is profound. By driving advancements in precision medicine and enabling deeper insights into genetic conditions, the dPCR market is at the forefront of transforming healthcare and improving patient outcomes worldwide.
Market Segmentation:
Consumable Segment to Dominate the Digital PCR Market (by Product)
Based on product, the global digital PCR market was led by the consumables segment, which held a 60.30% share in 2023. This substantial market share indicates the high demand for digital PCR consumables, including kits, assays, and reagents. The dominance of the consumable segment underscores the critical role of high-quality reagents and kits in digital PCR processes, facilitating reliable results and enhancing the overall effectiveness of genetic testing. This emphasis on consumables is essential for achieving accurate diagnoses and advancing personalized healthcare solutions, as they provide the necessary tools for precisely detecting and quantifying genetic variations.
Clinical and Research Application Segment to Dominate the Digital PCR Market (by Application)
Based on application, the global digital PCR testing market was led by the clinical and research application segment, which held an 86.48% share in 2023. The prominence of clinical and research applications underscores the critical role of digital PCR (dPCR) in enhancing diagnostic accuracy and advancing scientific inquiry. With its high precision and sensitivity, dPCR is essential across various fields, including oncology, infectious diseases, rare diseases, reproductive genetics, and transplant diagnostics.
This technology facilitates the effective quantification of nucleic acids, enabling early cancer detection and personalized treatment strategies. Additionally, dPCR provides accurate pathogen detection for infectious diseases and identifies genetic mutations associated with rare conditions. dPCR has become increasingly vital for delivering effective, personalized healthcare solutions by improving prenatal and postnatal screening and transplant monitoring.
Segmentation by Region
The digital PCR market in the North America region is expected to witness a significant growth rate of 16.04% during the forecast period. This notable growth can be attributed to several key factors. The increasing emphasis on personalized medicine has been driving demand for precise and sensitive diagnostic tools. Additionally, substantial investments in research and development from the public and private sectors have fostered innovation in dPCR technologies.
Furthermore, government initiatives focused on enhancing healthcare infrastructure and supporting research have significantly fueled the expansion of the dPCR market. However, the Asia-Pacific region is expected to reach $695.5 million in 2034 from $124.8 million in 2023, at a CAGR of 17.02% during the forecast period 2024-2034.
Recent Developments in the Digital PCR Market
- In September 2024, QIAGEN N.V. launched 100 new assays for its digital PCR (dPCR) platform, QIAcuity. These assays are intended for research in cancer, inherited genetic disorders, infectious disease monitoring, and food and environmental assessments.
- In June 2024, QIAGEN N.V. launched its new Custom Assay Design Tool for digital PCR (dPCR), specifically designed for copy number variation (CNV) analysis on the QIAcuity platform.
- In June 2024, Stilla Technologies launched two new digital PCR system configurations that have been added to the Nio product line, launched in November 2023 with the introduction of the flagship Nio+ instrument. The two new configurations are designed to deliver digital PCR solutions with a throughput that is fully tailored to the user's requirements.
- In April 2024, Bio-Rad Laboratories, Inc. collaborated with Oncocyte Corporation to develop and commercialize transplant monitoring products utilizing Bio-Rad's Droplet Digital PCR (ddPCR) instruments and reagents. As part of the agreement, Bio-Rad will participate in a private placement of Oncocyte's equity and has obtained exclusive commercial rights in specific markets to market Oncocyte's assay for transplant monitoring research with Bio-Rad's QX600 ddPCR System.
- In March 2023, Thermo Fisher Scientific launched its latest digital PCR research solution: the Applied Biosystems QuantStudio Absolute Q AutoRun dPCR Suite. This is the only digital PCR system on the market that facilitates lab automation while minimizing overhead costs, all without compromising consistency, flexibility, and user-friendliness.
Key Market Players and Competition Synopsis
Some prominent names established in the Digital PCR Market are:
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- F. Hoffmann-La Roche Ltd
- Standard BioTools Inc.
- Merck KGaA
- Stilla Technologies Inc.
- SAGA Diagnostics AB
- RevoSketch Inc.
- JN Medsys
- JETA Molecular BV.
- Sysmex Corporation
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 135 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value (USD) in 2024 | $776.2 Million |
| Forecasted Market Value (USD) by 2034 | $3350 Million |
| Compound Annual Growth Rate | 15.7% |
| Regions Covered | Global |
Key Topics Covered:
1 Markets
1.1 Market Overview
1.2 Trends: Current and Future Impact Assessment
1.2.1 Integration with Next-Generation Sequencing (NGS)
1.2.2 Increased Real-time Monitoring and Point-of-care Applications of Digital PCR
1.2.3 Increasing Product Launches in d-PCR Ecosystem
1.3 Supply Chain Overview
1.4 Research and Development Review
1.5 Ongoing Digital PCR Clinical Trials
1.6 Regulatory Landscape
1.7 Market Dynamics Overview
1.7.1 Market Drivers
1.7.1.1 Increasing Adoption of Personalized Medicine for Screening and Diagnostics of Genetic Disorders such as Rare Diseases and Cancer
1.7.1.2 Increasing Incidence of Infectious Diseases
1.7.1.3 Technological Advancement in dPCR to Enhance Market Growth
1.7.2 Market Restraints
1.7.2.1 High Cost of Platforms Associated with Digital-PCR
1.7.2.2 Shortage of Skilled Professionals and Trained Laboratory Technicians
1.7.3 Market Opportunities
1.7.3.1 Increased Use of Digital-PCR-Based Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plan
1.7.3.2 Growing Adoption of dPCR in Emerging Markets
2 Global Digital PCR Market, by Product, $Million, 2023-2034
2.1 Overview
2.2 Systems
2.2.1 Droplet Digital PCR Systems
2.2.2 Chip-Based Digital PCR Systems
2.3 Consumables (Kits, Assays, and Reagents)
2.4 Software and Services
3 Global Digital PCR Maret, by Application, $Million, 2023-2034
3.1 Overview
3.2 Clinical and Research Application
3.2.1 Oncology
3.2.1.1 Solid Tumor
3.2.1.2 Hematological Malignancies
3.2.2 Infectious Diseases
3.2.2.1 Respiratory Infections
3.2.2.2 Gastrointestinal Infections
3.2.2.3 Other Infections
3.2.3 Rare Diseases
3.2.3.1 Inherited Trait Type
3.2.3.2 Acquired Trait Type
3.2.4 Reproductive Genetics
3.2.4.1 Prenatal Diseases
3.2.4.2 Postnatal Diseases
3.2.5 Transplant Diagnostics
3.2.6 Other Clinical and Research Applications
3.3 Environmental Applications
3.4 Other Applications
4 Global Digital PCR Market, by End User, $Million, 2023-2034
4.1 Overview
4.2 Academic and Research Institutes
4.3 Hospitals and Clinics
4.4 Diagnostic Centers
4.5 Pharmaceutical and Biopharmaceutical Companies
4.6 Other End Users
5 Regions
6 Markets - Competitive Benchmarking & Company Profiles
6.1 Competitive Landscape
6.2 Market Share Analysis
6.3 Company Profiles
- Bio-Rad Laboratories
- Thermo Fisher Scientific
- QIAGEN
- F. Hoffmann-La Roche
- Standard BioTools
- Merck
- Stilla Technologies
- SAGA Diagnostics
- Naveris
- Genetron Holdings
- RevoSketch Inc.
- JN Medsys
- JETA Molecular
- Sysmex Corporation.
For more information about this report visit https://www.researchandmarkets.com/r/tiqwhl
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
